newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

IMMX
  • Immix Biopharma, Inc. will participate & host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY, from September 14-16, 2026.
  • Interested investors can request one-on-one meetings through their Morgan Stanley representative.
  • A link to the conference replay will be posted on the Immix website under the Presentation & Events page in the Investors section when available.
  • Immix Bio is a global leader in AL Amyloidosis, a disease where toxic light chains cause organ failure & death.
  • The company's lead candidate, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy with a proprietary digital filter designed to eliminate toxic light chain sources.
  • NXC-201 is currently being evaluated in the U.S. multi-center NEXICART-2 study (NCT06097832) with a potentially registrational design.
  • NXC-201 holds Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy designation, & Orphan Drug Designation from the U.S. FDA, plus Orphan Drug Designation from the EU EMA.